Glass House Brands Inc. Subordinate Voting Shares (GLAS) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.18 -4.39% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.16

Glass House Brands Inc. Subordinate Voting Shares (GLAS) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $200.6M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GLAS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is GLAS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Glass House Brands Inc. Subordinate Voting Shares (NYSE: GLAS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $2.18 (-4.39% 1D, market cap $200.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLAS ranks #1007 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does GLAS compare to NAGE and MDWD in the Health Care sector?
β–Ό

Within the Health Care sector (Medicinal Chemicals and Botanical Products), GLAS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 42.3%, and ROIC of -9.2%. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC β€”, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GLAS?
β–Ό

Per GLAS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001848731), Glass House Brands Inc. Subordinate Voting Shares generated $182.0M in revenue (-9.4% YoY), -$29.7M in net income, and -$15.7M in free cash flow against $318.6M in total assets and $68.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.16 (-0.98%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (18/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510018
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (3)Whales (3)SEC (6)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.9% Base Target
$15 Bull$2 Base$1 Bear
πŸ“¬ FREE GLAS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for GLAS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
πŸ” WHY GLAS SCORES 18/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (33% of score)

Altman Z-Score 0.38 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Cash Engine Quality+4/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 42.3% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
26
Grade E$4.08-39.7% Next Q
Q2 (-2Q)
23
Grade E$2.46-13% Next Q
Q3 (-1Q)
21
Grade E$2.14+1.9% Next Q
Current
18
Grade E$2.18-12.2% Hist 90D Ξ±
Trajectory: E (26) β†’ E (18)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a GLAS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While GLAS currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.03) and Max Pain ($2.29) forces dealer call-delta covering toward $14.63.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GLASβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œGLAS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLAS)

  • βœ“Walkthrough of GLAS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GLAS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -77.32%β–Ό DESCENDING CHANNEL
2026-11-02O $2.25H $2.28L $2.18C $2.18VOL 901.6K
RES: $6.99SUP: $0.54SMA50: $6.03SMA200: $8.79
$14.79$11.23$7.68$4.12$0.57RES $6.99SUP $0.54$2.182026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GLAS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -9.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GLAS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for GLAS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GLAS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLAS)

Health Care Rank #1007 of 1016 βš”οΈ NAGE vs GLAS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (GLAS vs. NAGE, MDWD, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Glass House Brands Inc. Subordinate Voting Shares (GLAS) ranks #1007 by composite RQD confidence (18/100, grade E) and #578 by equity capitalization ($200.6M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with GLAS at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GLAS ACTIVE
Glass House Brands Inc. Subordinate Voting Shares
E 18/100 β€” 42.3% -9.2% -4.39% $200.6M Benchmark Subject
NAGE
Niagen Bioscience Inc.
D+ 57/100 11.4x 64.3% 16.8% -6.80% $197.8M /nage-vs-glas β†’
MDWD
MediWound Ltd.
D 51/100 β€” β€” β€” -4.04% $178.9M /mdwd-vs-glas β†’
ACB
Aurora Cannabis Inc.
D+ 54/100 β€” β€” β€” -0.49% $252.8M /acb-vs-glas β†’
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% -0.21% $265.0M /usna-vs-glas β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001848731

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Glass House Brands Inc. Subordinate Voting Shares (GLAS) reported GAAP revenue of $182.0M (-9.4% vs. FY2024 revenue of $200.9M , and +13.1% cumulative change since FY2023) , GAAP net income of -$29.7M, operating cash flow of $11.4M, and free cash flow of -$15.7M (-186.9% YoY). On the balance sheet, GLAS closed FY2025 with $318.6M in total assets against $68.6M in total debt (Altman Z-Score: 0.38, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $182.0M -$29.7M $11.4M -$15.7M $318.6M $68.6M
FY2024 (FY) 2024-12-31 $200.9M $519.0K $28.4M $18.1M $310.5M $50.6M
FY2023 (FY) 2023-12-31 $160.8M -$98.3M $23.2M $23.2M β€” β€”

3. GLAS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GLAS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Glass House Brands Inc. Subordinate Voting Shares (NYSE: GLAS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $2.18 (-4.39% 1D, market cap $200.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLAS ranks #1007 in composite RQD confidence.

How does GLAS compare to NAGE and MDWD in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), GLAS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 42.3%, and ROIC of -9.2%. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC β€”, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GLAS?

Per GLAS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001848731), Glass House Brands Inc. Subordinate Voting Shares generated $182.0M in revenue (-9.4% YoY), -$29.7M in net income, and -$15.7M in free cash flow against $318.6M in total assets and $68.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GLAS trading relative to its 50-day, 200-day, and 52-week technical levels?

GLAS last traded at $2.18 (-4.39% on volume of 1,410,593 shares), positioning the stock -63.85% below its 50-day simple moving average ($6.03) and -75.20% below its 200-day simple moving average ($8.79). Across its 52-week range of $1.67 to $13.93, GLAS sits at the 4.2% percentile with a 14-day RSI of 17.2 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.91 to $2.45).

GLAS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does GLAS pay a dividend and is it safe?

Glass House Brands Inc. Subordinate Voting Shares (GLAS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

ROARABLE RATING BRIEF β€’ RQD 18/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

GLAS β€” Glass House Brands Inc. Subordinate Voting Shares: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 18 out of 100, graded E, with the verdict "Roarable Strong Sell β€” Forensic Risk / Avoid." Per the Roarable RQD rating, the five pillars score as follows:

  • Fundamental Cash Engine: 2 / 20. The pillar reflects ROIC of -9.2% and FCF yield of -7.84%. Both are negative, meaning the business is not currently generating returns on invested capital or free cash flow relative to its valuation.
  • Whale 13F Flow: 3 / 20. This pillar covers institutional accumulation and options positioning. It scores low, indicating limited institutional support in the rating's view.
  • Insider Conviction: 3 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. It scores low, indicating limited evidence of insider conviction in the rating's view.
  • Macro Regime Fit: 4 / 20. The pillar reflects a beta of 1.0 and sector sensitivity. It scores low, indicating the rating does not see a favorable macro alignment.
  • Forensic Balance Sheet: 6 / 20. The pillar reflects an Altman Z-Score of 0.38, a Piotroski F-Score of 5/9, and Debt/Equity of 0.93. The Altman Z-Score is low, which per the rating's framing signals financial distress risk; the Piotroski score is moderate.

For a prospective investor evaluating the stock today, the rating's pillars point in one direction: weak cash generation, limited institutional and insider support, and a stressed balance sheet. The primary upside argument rests on the share price being low relative to its 52-week range of $1.67 - $13.93, but the source data provides no valuation multiples (P/E, EV/EBITDA, EPS) against which to judge whether that price is attractive. Investors should treat the RQD verdict as the primary signal in the source data and weigh the forensic risk indicators heavily before any decision.

Business

Glass House Brands Inc. Subordinate Voting Shares (GLAS) is a NYSE-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the company profile. The source data does not describe its products, customers, or revenue model. Per the market data, the company reports a gross margin of 42.3%, an operating margin of -9.1%, and a net margin of -16.3%. Not available in source data for further business detail.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$182.0M$-16.5M$-29.7MN/A$-15.7MN/A$68.6M
FY 2024$200.9M$5.7M$0.5MN/A$18.1MN/A$50.6M
FY 2023$160.8M$-49.5M$-98.3MN/A$23.2MN/AN/A

Per the SEC financials, revenue declined from $200.9M in FY 2024 to $182.0M in FY 2025, and operating income moved from $5.7M to $-16.5M. Net income was $-29.7M in FY 2025 after $0.5M in FY 2024. Per the Roarable RQD rating and market data, ROIC is -9.2% and the net margin is -16.3%. The Altman Z-Score is 0.38 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.93 per the forensic balance sheet pillar. Cash balances are not available in source data.

Open Questions

  • What are the company's products, customers, and revenue mix, given the source data only identifies its sector and industry?
  • What is the current cash balance, and how does it compare to the $68.6M of debt reported for FY 2025?
  • What drove the swing from positive FY 2024 operating income ($5.7M) to negative FY 2025 operating income ($-16.5M)?
  • What are the P/E, EPS, and EV/EBITDA multiples, which would allow valuation against the $2.28 price?
  • Are there any analyst estimates, insider transactions, or institutional holdings data that would confirm or challenge the low pillar scores?

GLAS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Glass House Brands Inc. Subordinate Voting Shares (GLAS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to GLAS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GLAS Bull vs. Bear Conversation Board β€” What's Your Call at $2.18?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GLAS 🐻 67% BEARISH CONVICTION
1. Pick Your Side on GLAS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.01 (-11.8%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is GLAS (E β€’ RQD 18/100) a Buy at $2.28?

Welcome to the GLAS (Glass House Brands Inc. Subordinate Voting Shares) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.85 (-18.9%)
Spot @ $2.28

Pump the brakes on GLAS β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GLAS, but look at what you are paying: current EV/EBITDA multiples with 42.3% gross margins. Unless Glass House Brands Inc. Subordinate Voting Shares expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $2.90 (+27.2%)
Spot @ $2.28

GLAS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GLAS, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $2.28 (52-wk range $1.67 - $13.93), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%